The management seems aggressive in sharing the guidance like x2 Rev and x3 Profits. It is still unclear to me how the Assam contract can impact the overall realizations, and I don’t buy the reasoning on that front. Then there is a risk of this raid on the investor sentiments.
The only positive which I can derive is looking at the peer comparison to the likes of Lal path and thyrocare; even though the nature of our business is not precisely similar, the topline and margins impacts are significant there. In comparison, our business was more resilient owing to the growth in the core business. I also understand some ambiguity concerning realizations with the test counts, but the management has still not changed the 2024FYE guidance. So I guess, I lack some understanding of the business, and any interpretations or opinions are well appreciated.
Disc. Invested.
Subscribe To Our Free Newsletter |